A study evaluating the efficacy of right unilateral and bilateral repetitive transcranial magnetic stimulation for the treatment of depression.

Not Applicable

Completed

• Conditions: Treatment Resistant Depression; Mental Health - Depression

• Registration Number: ACTRN12610000998044
• Lead Sponsor: Healthscope

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11-17
• Last Update Posted: 2020-01-13

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 176

Inclusion Criteria

1.Have a Diagnostic and Statistical Manual -IV (DSM-IV) diagnosis of a major depressive episode.
2. Have failed to respond to adequate antidepressant medical therapy. This will be defined by at least two courses of antidepressant medication (from two medication classes) at therapeutic doses for a minimum of six weeks. Adequate daily dose will be considered to be a minimum of: 150mg of Imipramine or equivalent for tricyclic antidepressants, 20mg of Fluoxetine or equivalent for serotonin re-uptake inhibitors, 600mg of Moclobemide, 600mg of Nefazadone, 150mg of Venlafaxine, 60mg of Phenelzine or equivalent for monoamine oxidase inhibitors
3. Have a Hamilton Depression Rating Scale of > 16 (moderate – severe depression)
4. Have had no increase or initiation of new antidepressant therapy in the 4 weeks prior to screening.

Exclusion Criteria

Patients who:
1. Have an unstable medical condition, neurological disorder or any history of a seizure disorder or are currently pregnant or lactating,
2. In the opinion of the investigator, are a sufficient suicidal risk to require immediate electro-convulsive therapy,
3. Have a current DSM IV diagnosis of substance abuse or dependence disorder, a diagnosis of a personality disorder or another axis 1 disorder.

Study & Design

• Study Type: Interventional
• Study Design: Not specified